SciBase Announces Collaboration for Prediction of Atopic Dermatitis in Infants
SciBase Announces Collaboration for Prediction of Atopic Dermatitis in Infants
STOCKHOLM, Nov. 12, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, announced today its engagement in a collaboration with the SKIN Research Group of the Department of Dermatology at the Vrije Universiteit Brussel (VUB)/ University hospital in Brussels (UZ Brussels) for a study geared toward predicting atopic dermatitis (a special form of eczema) and concomitant atopic diseases, such as asthma and hay fever in infants.
斯德哥爾摩，2024年11月12日 /PRNewswire/ — 基於增強智能的皮膚病解決方案的領先開發商SciBase Holding Ab（「SciBase」）（STO：SCIB）今天宣佈與布魯塞爾自由大學（VUB）/布魯塞爾大學醫院（UZ Brussel）皮膚病系皮膚研究小組合作，進行一項旨在預測特應性的研究皮炎（一種特殊形式的溼疹）和伴隨的過敏性疾病，例如嬰兒的哮喘和花粉症。
SciBase is excited to announce a new collaboration aimed at revolutionizing early detection of atopic diseases in infants through the use of Electrical Impedance Spectroscopy (EIS) technology. This partnership seeks to unlock the potential of Nevisense to predict an infant's risk of developing these conditions, empowering researchers with critical insights early in a child's life. The data gathered will play a key role in developing an innovative product that could pave the way for improved healthcare outcomes for children worldwide. The collaboration will start immediately and will include hundreds of newborn children enrolled in the DIANA birth cohort who will be followed for 2 years.
SciBase 很高興地宣佈了一項新的合作，旨在通過使用電阻抗譜 (EIS) 技術徹底改變嬰兒特應性疾病的早期檢測。這種合作關係旨在釋放Nevisense預測嬰兒患上這些疾病的風險的潛力，爲研究人員提供在兒童生命早期的關鍵見解。收集的數據將在開發創新產品方面發揮關鍵作用，該產品可以爲改善全球兒童的醫療保健結果鋪平道路。合作將立即開始，將包括數百名加入DIANA出生隊列的新生兒，他們將接受爲期2年的隨訪。
Inge Kortekaas Krohn, assistant professor SKIN Research Group comments:
SKIN 研究小組助理教授 Inge Kortekaas Krohn 評論道：
'' Early detection of a child that is at risk of developing atopic dermatitis and subsequent adequate preventive measures can reduce disease burden and further progression to other atopic diseases like food allergy, allergic asthma or allergic rhinitis. Therefore, the present collaboration holds the potential to improve prediction, prevention and the prognosis of children at risk for development of eczema and may have clinical relevance for allergic diseases other than atopic dermatitis as well."
「及早發現有患特應性皮炎風險的兒童，並隨後採取適當的預防措施，可以減輕疾病負擔，進一步發展爲其他特應性疾病，例如食物過敏、過敏性哮喘或過敏性鼻炎。因此，目前的合作有可能改善有患溼疹風險的兒童的預測、預防和預後，也可能對特應性皮炎以外的過敏性疾病具有臨床意義。」
"We are thrilled about the potential this study holds to positively impact children and families, giving them the opportunity for a healthier start in life. At SciBase, our mission is to advance the prediction and prevention of diseases, and this collaboration aligns perfectly with our core values. The clinical products that may emerge from this partnership reflect our ongoing commitment to improving health outcomes for future generations. This study, as well as our separate collaboration with Kenvue, further reinforces our dedication to improving health outcomes for this patient population", says Pia Renaudin CEO SciBase.
「這項研究有可能對兒童和家庭產生積極影響，讓他們有機會過上更健康的人生起步，我們對此感到非常興奮。在 SciBase，我們的使命是推進疾病的預測和預防，這種合作完全符合我們的核心價值觀。此次合作可能產生的臨床產品反映了我們對改善子孫後代健康狀況的持續承諾。這項研究，以及我們與Kenvue的單獨合作，進一步增強了我們對改善這些患者群體的健康狀況的承諾。」 SciBase首席執行官皮亞·雷諾丁說。
For additional information, please contact:
Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]
欲了解更多信息，請聯繫：
首席執行官皮亞·雷諾丁，電話：+46732069802，電子郵件：[email protected]
Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: [email protected]
認證顧問 (CA)：
卡內基投資銀行 Ab（publ）
電話：+46 (0) 73 856 42 65
電子郵件：[電子郵件保護]
About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
關於 SciBase
SciBase 是一家全球醫療技術公司，專門從事皮膚病學的早期發現和預防。SciBase 開發並商業化了 Nevisense，這是一個獨特的即時護理平台，它結合了人工智能（人工智能）和先進的 EIS 技術，可提高診斷準確性，確保主動的皮膚健康管理。
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
我們的承諾是最大限度地減少患者的痛苦，使臨床醫生能夠通過及時的檢測和干預來改善和挽救生命，並降低醫療成本。
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
SciBase建立在瑞典斯德哥爾摩卡羅林斯卡研究所20多年的研究基礎上，是皮膚病學進步領域的領導者。
This information was brought to you by Cision
這些信息是由 Cision 帶給你的
The following files are available for download:
以下文件可供下載：
|
UZ brussel and SciBase PR eng |
|
UZ 布魯塞爾和 SciBase PR eng |
